Ischemic Heart Disease

2
Pipeline Programs
7
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Rhythm Pharmaceuticals
1 program
1
StentPhase 41 trial
Active Trials
NCT00476957Completed8,709Est. Jul 2014
GS
Gilead SciencesFOSTER CITY, CA
1 program
1
GS-6615Phase 11 trial
Active Trials
NCT01847391Completed36Est. Nov 2013
Abbott
AbbottABBOTT PARK, IL
3 programs
ABSORB GT1 BVSN/A1 trial
MINI TREK RX 1.20 mm Coronary Dilatation CatheterN/A1 trial
XIENCE Xpedition 2.25 mm stentN/A1 trial
Active Trials
NCT03409731Completed135Est. Feb 2023
NCT01186198Completed71Est. Dec 2010
NCT02513732Completed100Est. Sep 2020
Precision BioSciences
1 program
Laboratory Biomarker AnalysisN/A1 trial
Active Trials
NCT03064360Completed200Est. Jan 2020
Biotronik
BiotronikGermany - Berlin
1 program
Orsiro Sirolimus Eluting Coronary Stent SystemN/A1 trial
Active Trials
NCT03600961Terminated173Est. Dec 2021
Astellas
AstellasChina - Shenyang
1 program
Using Duke Activity Status Index (DASI) to Select Optimal Cardiac Stress TestsN/A1 trial
Active Trials
NCT00907855Completed200
C
CordisFL - Miami Lakes
1 program
kissing balloon inflationN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Rhythm PharmaceuticalsStent
Gilead SciencesGS-6615
BiotronikOrsiro Sirolimus Eluting Coronary Stent System
Precision BioSciencesLaboratory Biomarker Analysis
AbbottABSORB GT1 BVS
AbbottXIENCE Xpedition 2.25 mm stent
AbbottMINI TREK RX 1.20 mm Coronary Dilatation Catheter
AstellasUsing Duke Activity Status Index (DASI) to Select Optimal Cardiac Stress Tests

Clinical Trials (8)

Total enrollment: 9,624 patients across 8 trials

NCT00476957Rhythm PharmaceuticalsStent

Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)

Start: Jun 2007Est. completion: Jul 20148,709 patients
Phase 4Completed
NCT01847391Gilead SciencesGS-6615

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

Start: May 2013Est. completion: Nov 201336 patients
Phase 1Completed
NCT03600961BiotronikOrsiro Sirolimus Eluting Coronary Stent System

BIOFLOW-SV Portugal Registry

Start: Jul 2018Est. completion: Dec 2021173 patients
N/ATerminated
NCT03064360Precision BioSciencesLaboratory Biomarker Analysis

Early Prediction of Major Adverse Cardiovascular Events Using Remote Monitoring

Start: Feb 2017Est. completion: Jan 2020200 patients
N/ACompleted
NCT03409731AbbottABSORB GT1 BVS

Absorb GT1 Japan PMS

Start: Dec 2016Est. completion: Feb 2023135 patients
N/ACompleted
NCT02513732AbbottXIENCE Xpedition 2.25 mm stent

XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS)

Start: Jul 2014Est. completion: Sep 2020100 patients
N/ACompleted
NCT01186198AbbottMINI TREK RX 1.20 mm Coronary Dilatation Catheter

A Clinical Evaluation of the MINI TREK RX 1.20 mm Coronary Dilatation Catheter in Stenotic Lesions

Start: Aug 2010Est. completion: Dec 201071 patients
N/ACompleted
NCT00907855AstellasUsing Duke Activity Status Index (DASI) to Select Optimal Cardiac Stress Tests

Using Duke Activity Status Index (DASI) to Select Optimal Cardiac Stress Tests

Start: Apr 2009200 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space